Greg Hodge and Sandra Hodge
Steroid resistant CD8+CD28(null) NKT-like pro-inflammatory cytotoxic cells in chronic obstructive pulmonary disease
Frontiers in Immunology, 2016; 7(DEC):617-1-617-6

Copyright © 2016 Hodge and Hodge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Originally published at:
http://doi.org/10.3389/fimmu.2016.00617

http://hdl.handle.net/2440/105895
Steroid Resistant CD8⁺CD28null NKT-Like Pro-inflammatory Cytotoxic Cells in Chronic Obstructive Pulmonary Disease

Greg Hodge¹,²,³* and Sandra Hodge¹,²,³

¹ Chronic Inflammatory Lung Disease Research Laboratory, Lung Research Unit, Hanson Institute, Adelaide, SA, Australia, ² Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia, ³ Department of Medicine, University of Adelaide, Adelaide, SA, Australia

Corticosteroid resistance is a major barrier to effective treatment in chronic obstructive pulmonary disease (COPD), and failure to suppress systemic inflammation in these patients may result in increased comorbidity. Although much of the research to date has focused on the role of macrophages and neutrophils involved in inflammation in the airways in COPD, recent evidence suggests that CD8⁺ T cells may be central regulators of the inflammatory network in this disease. CD8⁺ cytotoxic pro-inflammatory T cells have been shown to be increased in the peripheral blood and airways in patients with COPD, whereas smokers that have not progressed to COPD only show an increase in the lungs. Although the mechanisms underlying steroid resistance in these lymphocytes is largely unknown, new research has identified a role for cytotoxic pro-inflammatory CD8⁺ T-cells and CD8⁺ natural killer T-like (NKT-like) cells. Increased numbers of these cells and their significant loss of the co-stimulatory molecule CD28 have been shown in COPD, consistent with findings in the elderly and in clinical conditions involving chronic activation of the immune system. In COPD, these senescent cells expressed increased levels of the cytotoxic mediators, perforin and granzyme b, and the pro-inflammatory cytokines, IFNγ and TNFα. They also demonstrated increased cytotoxicity toward lung epithelial cells and importantly were resistant to immunosuppression by corticosteroids compared with their CD28⁺ counterparts. Further research has shown these cells evade the immunosuppressive effects of steroids via multiple mechanisms. This mini review will focus on cytotoxic pro-inflammatory CD8⁺CD28null NKT-like cells involved in COPD and novel approaches to reverse steroid resistance in these cells.

Keywords: CD8⁺ NKT-like cell, steroid resistance, chronic obstructive pulmonary disease, CD28, IFNγ and TNFα, Pgp, HDAC2, Hsp90

CD8⁺ NATURAL KILLER T-LIKE (NKT-LIKE) CELLS IN CHRONIC OBSTUCTIVE PULMONARY DISEASE (COPD)

Natural killer T-like cells comprise a unique subgroup of lymphocytes that express features of both T cells and natural killer (NK) cells. NKT-like cells co-express T-cell receptors and CD4 or CD8 (or CD4⁻/CD8⁻), together with markers associated with NK cells, such as CD56 (Figure 1C) and/or CD16 or CD161. Acquisition of CD11b represents an early event in CD8⁺ T-cell differentiation, which may allow extravasation to peripheral tissues (1, 2). These cells are a small but important...
subset of lymphocytes that represent a bridge between innate and adaptive immunity.

There has been conflicting evidence regarding changes in NKT-like cell numbers in COPD. Numbers of these cells have been reported to be decreased in the peripheral blood of patients with COPD (3). One study showed numbers to be unchanged (4), while a third reported increased numbers (5). However, further characterization into CD4+ or CD8+ NKT-like cells was not performed in any of these reports. NKT-like cells have also been reported to be increased in induced sputum and bronchoalveolar lavage (BAL) of COPD patients and, importantly, have been shown to be cytotoxic to autologous lung cells (3, 4, 6).

**LOSS OF CD28 ON SENESCENT LYMPHOCYTES IN COPD**

Following persistent antigenic stimulation, NKT-like cells can lose co-stimulatory molecules, undergo telomere shortening, and exhibit defective IL-2 production; changes that define the state of replicative senescence. The majority of these “effector senescent” lymphocytes are CD8+, CD45RA+, CD11a<sup>high</sup>, CD28<sup>null</sup> (Figure 1D), CD62L<sup>−</sup>, and CCR7<sup>−</sup>. Expansion of these cells are found in the elderly and in other clinical conditions involving chronic activation of the immune system such as viral infections, rheumatic, and autoimmune diseases (7). Increased numbers have also been reported in chronic inflammatory lung diseases including COPD and in patients following lung transplantation (8, 9).

**STEROID RESISTANCE IN CD8+CD28<sup>null</sup> NKT-LIKE CELLS IN COPD**

Steroid Resistant CD8+ T Cells in COPD

Patients with COPD have been shown to be resistant to the immunosuppressant effects or glucocorticoids (10). Most of the investigations into steroid resistance in this disease have focused on the role of the airway macrophages and neutrophils (10); however,

---

**FIGURE 1** | Flow cytometric gating technique used to identify CD8<sup>+</sup>CD28<sup>+</sup> natural killer T-like (NKT-like) cells (and CD8<sup>+</sup>CD28<sup>+</sup> NKT-like cells) from the peripheral blood of patients with chronic obstructive pulmonary disease. (A) Identification of lymphocytes as CD45<sup>+</sup> low side scatter (SSC) events. (B) Removal of red blood cell contaminations removed by lymphocyte gating using forward scatter vs. SSC characteristics. (C) Identification of NKT-like cells as CD3<sup>−</sup>CD56<sup>+</sup> events. (D) Identification of CD28<sup>+</sup> and CD28<sup>+</sup> NKT-like cells using CD8<sup>+</sup> vs. CD8<sup>+</sup> staining. (E) Expression of IFNγ and histone deacetylase (HDAC)2 in CD8<sup>+</sup>CD28<sup>+</sup> and CD8<sup>+</sup>CD28<sup>+</sup> cells. (F) Expression of P-glycoprotein-1 (Pgp1), glucocorticoid receptor (GCR), and heat shock protein (Hsp)90 expression in CD8<sup>+</sup>CD28<sup>+</sup> and CD8<sup>+</sup>CD28<sup>+</sup> cells. Note: the majority of NKT-like cells are CD8<sup>+</sup> and CD28<sup>+</sup> NKT-like cells (Pgp1 unchanged).
the mechanisms underlying steroid resistance in lymphocytes in patients with COPD until recently has been largely unknown. The role of T-cells is likely to be important in this regard, as their increased numbers have been reported in the lungs of patients with COPD. A study by Maeno et al. demonstrated an important requirement for CD8+ T cells in the development of cigarette smoke-induced emphysema. They suggested a unifying pathway whereby CD8+ T cells are the central regulators of the inflammation network in COPD (11). Inhaled corticosteroids have been shown to reduce exacerbation rates and improve health status in patients with COPD but can also increase the risk of pneumonia (12, 13). The numbers of bronchial CD8+ T-cells were reduced following long-term treatment with inhaled corticosteroids in ex-smoker COPD patients only but not persistent COPD smokers (12, 13).

There have been reports of increased numbers of CD8+ T cells in the peripheral blood, BAL, and lung parenchyma from COPD smoker and ex-smoker patients compared with healthy smokers and control subjects (14, 15). This indicates the systemic involvement of these cells in COPD. The production of the pro-inflammatory cytokines, IFNγ and TNFα, by CD8+ T cells was increased from peripheral blood, BAL, and intraepithelial compartments in patients with COPD. This was regardless of whether patients were receiving inhaled corticosteroids (14) indicating the lack of effectiveness of steroids at reducing pro-inflammatory cytokines by these cells. However, further lymphocyte subtyping with NKT-like cell markers was not performed. Steroid resistance was further shown in vitro by assessing the production of IFNγ by follicular CD8+ T cells in the presence of 0.1–1 µM dexamethasone (16), although further subtyping of NKT-like subsets was not performed in the study. Recently, steroid resistant CD8+CD28null NKT-like cells were reported to be increased in number and to express increased levels of the cytotoxic mediators, perforin and granzyme b. Pro-inflammatory cytokines, IFNγ and TNFα (8), were also increased in the peripheral blood of patients with COPD, confirming the important role of these lymphocytes in steroid resistance.

**P-glycoprotein-1 (Pgp1) in CD8+CD28null NKT-Like Cells**

P-glycoprotein is a transmembrane efflux pump well-characterized in drug-resistant cancer cells (17) and also thought to play a role in the function of steroid resistant lymphocytes in COPD. Pgp1 expression has been shown to be increased in T, NKT, and NK cells that also co-express IFNγ, TNFα, and granzyme b, in peripheral blood from COPD patients compared with healthy controls (Figure 1). However, further differentiation of NKT-like cells into CD4+ and CD8+ subsets was not performed (18).

Recent further investigations by the same authors comparing COPD patients with healthy age-matched controls showed no difference in Pgp1 expression between CD8+CD28null NKT-like and CD28+CD8+ NKT-like subsets. However, the percentages of CD8+Pgp1+CD28null NKT-like and CD8+Pgp1+CD28+ NKT-like cells were both increased in the COPD group (8) (Figure 2A). Treatment with very low-dose cyclosporine A (CsA), a Pgp1 inhibitor (2.5 ng/ml; approximately 25 times less than that used for transplant rejection therapy), combined with standard dose corticosteroid [1 µM prednisolone (pred)] resulted in synergistic inhibition of pro-inflammatory cytokines in CD8+Pgp1+CD28null NKT-like cells (18) (Figure 2B). These data indicate that these agents may be an effective add-on therapy to standard steroid treatment.

**Loss of Glucocorticoid Receptor (GCR) in CD8+CD28null NKT-Like Cells in COPD**

Glucocorticoids must bind to the GCR in the cytoplasm of a cell before being transported to the nucleus. A recent study examined the expression of GCR in pro-inflammatory NKT-like cells in the peripheral blood of patients with COPD (8). COPD was associated with increased percentage of CD28null NKT-like cells compared with healthy controls. Loss of CD28 was associated with an increase in percentage of NKT-like cells producing IFNγ and TNFα and importantly, with a loss of GCR (8) (Figure 2C). A significant loss of GCR in CD8+CD28null NKT-like cells was noted in both COPD patients and controls compared with CD8+CD28+ NKT-like cells (mean ± SEM: 9 ± 4% CD8+GCR+CD28null NKT-like cells vs. 39 ± 7% CD8+GCR+CD28+ NKT-like cells in COPD). There was a significant correlation between GCR expression and IFNγ and TNFα production by CD8+ NKT-like cells. Taken together, these data show a loss of GCR in senescent CD8+CD28null NKT-like cells and suggest that alternate treatment options to glucocorticoids are required to suppress pro-inflammatory cytokine production in patients with COPD.

**Decreased Histone Deacetylase (HDAC)2 in CD8+CD28null NKT-Like Cells in COPD**

Histone acetyltransferases and HDAC are enzymes that upregulate and downregulate pro-inflammatory gene transcription, respectively. HDAC2 is required by corticosteroids to switch off activated inflammatory genes and is reduced in lung macrophages in COPD (10). A recent study showed that HDAC2 expression was suppressed in pro-inflammatory CD8+CD28null NKT-like cells in patients with COPD (19) and negatively correlated with the percentage of CD8+CD28null NKT-like cells producing IFNγ or TNFα in all subjects (e.g., COPD: R = −0.789, p < 0.001 for CD8+CD28null NKT-like cells producing IFNγ) (Figure 2D). Theophylline is an activator of HDAC and enhances the anti-inflammatory effects of corticosteroids in alveolar macrophages in COPD patients (20). Addition of theophylline has recently been shown to increase the anti-inflammatory effects of steroids in senescent lymphocytes from COPD patients (18). Addition of low-dose theophylline (5 mg/l) induced a synergistic upregulation of HDAC2 in CD8+CD28null NKT-like cells in the presence of 1 µM pred and 2.5 ng/ml CsA (Figure 2E). This was associated with a decrease in pro-inflammatory cytokine production by these cells. These findings suggest this form of therapy may enhance the anti-inflammatory effects of steroids and thus reduce inflammation caused by these cells in COPD.

**Decreased Heat Shock Protein (Hsp)90 in CD8+CD28null NKT-Like Cells in COPD**

Glucocorticoid receptor must be bound to molecular chaperones Hsp70 and Hsp90 to acquire a high-affinity steroid binding
Glucocorticoids enter cells by overcoming membrane drug efflux pump P-glycoprotein-1 (Pgp1) and binding to the glucocorticoid receptor (GCR) in the cytoplasm. GCR must be bound to the molecular chaperones heat shock protein (Hsp)70 and Hsp90 to acquire a high-affinity steroid binding conformation, and traffic to the nucleus where engagement of histone deacetylases (HDACs), particularly HDAC2, results in reduction of pro-inflammatory gene activation. In COPD compared with age-matched healthy control subjects:

(A) Pgp1+ NKT-like cells are increased in COPD, reducing intracellular levels of GC. Expression of GCR (C), Hsp90 (F), and HDAC2 (D) are decreased in CD8+CD28null NKT-like cells (no change in Hsp70 (G) reducing steroid effectiveness.

(i) The percentage of steroid resistant CD8+CD28nullCD137+ NKT-like cells is increased. Possible therapeutic targeting to overcome steroid resistance CD8+CD28null NKT-like cells in COPD:

(B) Pgp1 is synergistically decreased in the presence of 2.5 ng/ml cyclosporine A (CsA) and 1µM prednisolone (pred).

(H) Hsp90 expression is increased in the presence of 2.5 ng/ml CsA and 1µM pred.

(E) HDAC2 expression is increased in the presence of 5 mg/ml theophylline, 2.5 ng/ml CsA, and 1µM pred.

(J) Blocking CD137 expression with anti-CD137 antibody. This targeting results in decreased IFNγ and TNFα pro-inflammatory cytokine expression.

There is increasing evidence that oxidative stress is important in the pathogenesis of COPD (27, 28). Oxidative stress occurs due to an increase of reactive oxygen species (ROS) causing damage to lipids, proteins, and DNA. Increased burden of oxidants from

**DOES OXIDATIVE STRESS PLAY A ROLE IN STEROID RESISTANCE IN NKT-LIKE CELLS?**

The loss of CD28 on CD8+CD28null NKT-like cells from COPD subjects has been reported to be associated with an upregulation of the “alternate” co-stimulatory molecule CD137 (4-1BB) (24) (Figure 2I). Targeting CD137 has been shown to be effective in treatment of rheumatoid arthritis and may thus be effective in other diseases associated with increased expression of this co-stimulatory molecule, including COPD (25). In vitro studies showed that blocking CD137 with an anti-CD137 antibody following PHA stimulation of PBMC from COPD patients resulted in a decrease in the percentage of CD8+CD28null NKT-like cells producing IFNγ, TNFα, and granzyme b production (26) compared with CD8+CD28+ NKT-like cells (Figure 2I), whereas stimulatory CD137 antibody increased production of these molecules. This indicates that targeting CD137 with anti-CD137 antibody may have novel therapeutic options for reducing inflammation in patients with COPD.
cigarette smoke and air pollutants and from ROS and reactive nitrogen species (RNS) released from inflammatory neutrophils, eosinophils, macrophages, and epithelial cells occurs in the lungs of COPD patients (27–29). The aging process is associated with a decrease in the antioxidant defense mechanisms in the lung resulting in increased ROS and RNS (30). Although there is a causal link between ROS, COPD, and aging in cellular senescence in many cells in the lung, sensitivity of individual lymphocyte subsets to oxidative stress and how this process affects disease progression remains largely unknown (30). While one study showed an association between ROS and cellular senescence in lymphocytes, some markers of oxidative stress were decreased (31). Increasing concentrations of ROS has been shown to suppress Th1 cells and increase Th2 cells, findings at odds with ours and many others in patients with COPD (30). Furthermore, it has been shown that neutrophils in the inflamed lung produce large amounts of ROS, which suppress T cells, while macrophages secrete cysteine and thioredoxin, which increase oxidation resistance of T cells (32). Although oxidative stress has been shown to inhibit expression of GCRs in total blood leukocytes, the effect on T and NKT-like cells was not determined (33). It is clear further research is needed specifically on the effect of ROS on T cell and NKT-like cell biology (32).

**FUTURE THERAPY FOR COPD**

Lymphocyte senescence and glucocorticoid resistance have been described in several other inflammatory conditions such as cardiovascular disease (34), autoimmune disease (35), arthritis (36), IBD (37) associated with aging (38), and aging with associated inflammation in COPD (39). Some of these conditions are associated with respiratory muscle dysfunction resulting in further increases in ROS and oxidative stress (40). CD28null T cells have been reported in patients with asthma (41), another inflammatory lung disease also associated with increased ROS and oxidative stress (42). Interestingly, several of these inflammatory diseases are also comorbid conditions associated with COPD (10) and therefore may also be associated with increased cytotoxic/pro-inflammatory CD8+CD28null NKT-like cells. Hence, targeting the pro-inflammatory nature of these cells by decreasing the expression of Pgp1 and/or CD137 and increasing the expression of GCR, HDAC2, and Hsp90 by CD8+CD28null NKT-like cells may reduce inflammation (Figure 2K) associated with a range of steroid resistant diseases including COPD and comorbid conditions associated with COPD. Furthermore, targeting these cytotoxic/pro-inflammatory cells at early onset of COPD may prevent the inevitable spiral of worsening lung function, and associated comorbidity of this progressive debilitating disease, and reduce the associated massive health-care costs (43).

**REFERENCES**

1. Arosa FA. CD28+CD28- T cells: certainties and uncertainties of a prevalent human T-cell subset. *Immunol Cell Biol* (2002) 80:1–13. doi:10.1046/j.1440-1711.2002.01057
2. Fiorentini S, Licenziata S, Alessandri G, Castelli F, Calligaris S, Bonafeo M, et al. CD11b expression identifies CD8+CD28+ T lymphocytes with phenotype and function of both naive/memory and effector cells. *J Immunol* (2001) 166(2):900–7. doi:10.4049/jimmunol.166.2.900
3. Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fiarclough LC. Altered effector function of peripheral cytotoxic cells in COPD. *Respir Res* (2009) 10:53. doi:10.1186/1465-9921-11-76
4. Hodge G, Mukaro V, Holmes M, Reynolds PN, Hodge S. Enhanced cytotoxic function of natural killer T-like cells associated with decreased CD94 (Kp43) in the chronic obstructive pulmonary disease pathway. *Respirology* (2013) 18(2):369–76. doi:10.1111/j.1440-1843.2012.02287
5. Tang Y, Xiaodan L, Wang M, Zou Q, Zhao S, Bowen S, et al. Increased numbers of NK cells, NKT-like cells and NK inhibitory receptors in peripheral blood of patients with chronic obstructive pulmonary disease. *Clin Dev Immunol* (2013) 2013:721782. doi:10.1155/2013/721782
6. Freeman CM, Stolberg VR, Crudgington S, Martinez FJ, Han MK, Chenseau SW, et al. Human CD56+ cytotoxic lung lymphocytes kill autologous lung cells in chronic obstructive pulmonary disease. *PLOS One* (2014) 9(7):e103840. doi:10.1371/journal.pone.0103840
7. Tarazona R, DelaRosa O, Alonso C, Osto R, Espejo I, Pena J, et al. Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescence T cells. *Mech Ageing Dev* (2001) 121:77–88. doi:10.1016/j.dci.2008.06.003
8. Hodge G, Jersmann H, Tran HB, Holmes M, Reynolds PN, Hodge S. Lymphocyte senescence in COPD is associated with loss of glucocorticoid receptor expression by pro-inflammatory/cytotoxic lymphocytes. *Respir Res* (2015) 16:2. doi:10.1186/s12931-014-0161-7
9. Hodge G, Hodge S, Li-Liew C, Reynolds PN, Holmes M. Increased natural killer T-like cells are a major source of pro-inflammatory cytokines and granymes in lung transplant patients. *Respirology* (2012) 17(1):155–63. doi:10.1111/j.1440-1843.2011.02075
10. Barnes PJ. Glucocorticosteroids: current and future directions. *Br J Pharmacol* (2011) 163:29–43. doi:10.1111/j.1476-5381.2010.01999
11. Maeno T, Houghton AM, Quintero PA, Grumelli S, Owen CA, Shapiro SD. CD8+ T cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. *J Immunol* (2007) 178(2):8090–6. doi:10.4049/jimmunol.1465-9921-14-13
12. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maalen TK. Randomised, doubleblind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ* (2000) 320(7245):1297–303. doi:10.1136/bmj.320.7245.1297
13. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* (2008) 178:332–8. doi:10.1164/rccm.200712-1869OC
14. Hodge G, Nairne J, Holmes M, Reynolds PN, Hodge S. Increased intracellular T helper 1 pro-inflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD patients. *Clin Exp Immunol* (2007) 150:22–9. doi:10.1111/j.1365-2249.2007.03451.x

**AUTHOR CONTRIBUTIONS**

GH and SH organized, wrote, and edited the manuscript. Figures were drawn by GH and edited by SH.

**FUNDING**

This work was supported by a Project Grant (626972); a R.D. Wright Biomedical Career Development Fellowship (1045511) from the National Health and Medical Research Council, Australia; a Lung Foundation Australia/A Menarini COPD Research grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
15. Saetta M, Baraldo S, Corbino L, Turato G, Bracciioni F, Rea F, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* (1999) 160(2):711–7. doi:10.1164/ajccm.160.2.9812020

16. Kaur M, Smyth LJC, Cadden P, Grundy S, Ray D, Plumb J, et al. T lymphocyte insensitivity to corticosteroids in chronic obstructive pulmonary disease. *Respir Res* (2012) 13:20. doi:10.1186/1465-9921-13-20

17. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM. Expression of a multidrug resistant gene in human tumors and tissues. *Proc Natl Acad Sci U S A* (1987) 84:265–9. doi:10.1073/pnas.84.1.265

18. Hodge G, Holmes M, Jersmann H, Reynolds PN, Hodge S. The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD. *Respir Res* (2013) 14:63. doi:10.1186/1465-9921-14-63

19. Hodge G, Jersmann H, Tran HB, Roscioli E, Holmes M, Reynolds PN, et al. Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes. *Respir Res* (2015) 16:130. doi:10.1186/s12931-015-0287-2

20. Barnes PJ. Theophylline for COPD. *Thorax* (2006) 61(9):742–4. doi:10.1136/thx.2006.061002

21. Xu L, Massaque J. Nuclear-cytoplasmic shuttling of signal transducers. *Nat Rev Mol Cell Biol* (2004) 5(3):209–19. doi:10.1038/nrm1331

22. Hodge G, Roscioli E, Jersmann H, Tran HR, Holmes M, Reynolds PN, et al. Steroid resistance in COPD is associated with impaired molecular chaperone Hsp90 expression by pro-inflammatory lymphocytes. *Respir Res* (2016) 17(1):1–12. doi:10.1186/s12931-016-0450-4

23. Hoffmann K, Handschumacher RE. Cyclophilin-40: evidence for a dimeric complex with hsp90. *Biochem J* (1995) 308:579–84. doi:10.1042/bj308579

24. Hodge G, Mukaro V, Reynolds PN, Hodge S. Role of CD8/CD28(null) T-cells and alternate co-stimulatory molecules in chronic obstructive pulmonary disease. *Clin Exp Immunol* (2011) 166(1):94–102. doi:10.1111/j.1365-2249.2011.04455

25. Jones D. Halting disease in its tracks. *Nat Rev Drug Discov* (2004) 3:909. doi:10.1038/nrd1692

26. Hodge G, Holmes M, Jersmann H, Reynolds PN, Hodge S. Targeting peripheral blood pro-inflammatory cytotoxic lymphocytes by inhibiting CD137 expression: novel potential treatment for COPD. *BMC Pulm Med* (2014) 14:85. doi:10.1186/1471-2466-14-85

27. Rahman I, Kinnula V. Strategies to decrease ongoing oxidant burden in chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol* (2012) 5(3):293–309. doi:10.1586/ercp.12.16

28. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. *Proc Am Thorac Soc* (2005) 2:258–66. doi:10.1513/pats.200504-045SR

29. Bernardo I, Bozilovski S, Vilhos R. Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities. *Pharmacol Ther* (2015) 155:60–79. doi:10.1016/j.pharmthera.2015.08.005

30. Kesarwani P, Murali A, Al-Khami A, Mehrota S. Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. *Antioxid Redox Signal* (2013) 18(12):1497–523. doi:10.1089/ars.2011.0473

31. Wiley L, Ashok D, Martin-Ruiz C, Talbot DCS, Collerton J, Kingston A, et al. Reactive oxygen species production and mitochondrial dysfunction in white blood cells are not valid biomarkers of aging in the very old. *PLoS One* (2014) 9(3):e91005. doi:10.1371/journal.pone.0091005

32. Belikov AV, Schraven B, Simonetti L. T cells and reactive oxygen species. *J Biomed Sci* (2015) 22:85. doi:10.1186/s12929-015-0194-3

33. Zeng M, Li Y, Jiang Y, Lu G, Huang X, Guan K. Local and systemic oxidative stress status in chronic obstructive pulmonary disease patients. *Can Respir J* (2013) 20(1):35–41. doi:10.1155/2013/985382

34. Teo FH, de Oliveira RT, Mamoni RL, Ferreira MC, Nadruz W, Coelho OR, et al. Characterisation of CD4+CD28null T-cells in patients with coronary artery disease and individuals with risk factors for atherosclerosis. *Cell Immunol* (2013) 281:11–9. doi:10.1016/j.cellimm.2013.01.007

35. Thewissen M, Somers V, Hellings N, Fraussen J, Danoiseaux J, Stinissen P. CD4+CD28null T-cells in autoimmune disease: pathologic features and decreased susceptibility to immunoregulation. *J Immunol* (2007) 179(10):6514–23. doi:10.4049/jimmunol.179.10.6514

36. Fasth AE, Snir O, Johansson AA, Nordmark B, Rahbari A, Klint E, et al. Skewed distribution of pro-inflammatory CD4+CD28null T-cells in rheumatoid arthritis. *Arthritis Res Ther* (2007) 9(5):R87. doi:10.1186/ar2286

37. Yokoyama Y, Fukunaga K, Ikeuchi H, Hamikozuru K, Hida N, Ohda Y, et al. The CD4CD28null and the regulatory CD4+CD28High T-cell phenotypes in patients with ulcerative colitis during active and quiescent disease, following colectomy. *Cytokine* (2011) 56(2):466–70. doi:10.1016/j.cyto.2011.06.021

38. Vallejo AN. CD28 extinction in human T-cells: altered functions and the program of T-cell senescence. *Immunol Rev* (2005) 205:158–69. doi:10.1111/j.0105-2896.2005.00256.x

39. Yao H, Homan I. Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPD. *Am J Physiol Lung Cell Mol Physiol* (2012) 303:557–66. doi:10.1152/ajplung.00175.2012

40. Zuo L, Hallman AH, Yousif MK, Chien MT. Oxidative stress, respiratory muscle dysfunction, and potential therapeutics in chronic obstructive pulmonary disease. *Front Biol* (2012) 7:506–13. doi:10.1007/s11515-012-1251-x

41. Hodge S, Hodge G, Simpson J, Yang IA, Upham J, James A, et al. Blood cytokotoxic/inflammatory mediators in non-eosinophilic asthma. *Clin Exp Immunol* (2012) 166(1):94–102. doi:10.1111/j.1365-2176.2011.09817.x

42. Jiang L, Diaz PT, Best TM, Stimpfl JN, He F, Zuo L. Molecular characterization of redox mechanisms in allergic asthma. *Ann Allergy Asthma Immunol* (2014) 113(2):137–42. doi:10.1016/j.anai.2014.05.030

43. Vermeire P. The burden of chronic obstructive pulmonary disease. *Respir Med* (2002) 96(Suppl C):S3–10. doi:10.1016/S0954-6110(02)80028-2

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.